Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: An observational study of 9246 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 3, 2009, Pages 292-299

  Augustin, M ^a   Ehrle, S ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Essex Pharma GmbH   (Germany)

Author keywords

Chronic idiopathic urticaria; Desloratadine; H1 receptor antagonist; Outcomes research; Quality of life

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CORTICOSTEROID; DESLORATADINE; FEXOFENADINE; LORATADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; SLEEP; SOMNOLENCE; URTICARIA; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; SLEEP; URTICARIA; YOUNG ADULT;

EID: 60049091787     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.03034.x     Document Type: Article

References (18)

1. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007 34 : 294 301.
2. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004 14 : 214 220.
3. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR, Villanueva Carreto Mde L, Guidos Fogelbach GA. [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.] Rev Alerg Mex 2004 51 : 181 188 (in Spanish).
4. Ozkan M, Ozkan M, Oflaz SB et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007 99 : 29 33.
5. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006 154 : 294 298.
6. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007 87 : 196 205.
7. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006 61 : 316 320.
8. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy, 2006 61 : 321 331.
9. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001 40 : 72 76.
10. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol, 2003 48 : 535 541.
11. Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol, 2007 8 : 37 42.
12. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Derm Venerol 2008 22 : 87 93.
13. Victor N, Windeler J, Hasford J et al. Empfehlungen zur Durchführung von Anwendungsbeobachtungen. Informatik Biometrie Epidemiologie Med Biologie 1997 28 : 247 252.
14. Bundesinstitut für Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9. Mai 2007.
15. Bachert C, Virchow CJ, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin Drug Invest 2002 22 (Suppl. 2 43/52.
16. Lachapelle JM, Decroix J, Henrijean A et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2006 20 : 288 292.
17. Rottem M, Elbirt D, Sthoeger Z Desloratadine Study Group. Desloratadine for chronic idiopathic urticaria. Harefuah 2005 144 : 547 553.
18. Di Lorenzo G, Pacor ML, Mansueto P et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004 114 : 619 625.